Acute Kidney Injury and ICU Nephrology

A single patient, six hours into septic shock resuscitation with rising norepinephrine requirements and early oliguric kidney injury. The disagreement is which second agent, if any, actually protects the kidney rather than just the blood pressure number.

A single patient, thirty-six hours post-op and newly oliguric. The disagreement is whether to use a single diuretic dose as a functional test of tubular reserve before deciding how much more fluid he actually needs, or to keep treating the oliguria as evidence he is still behind on volume.

A single patient, five days after valve surgery, still volume overloaded despite escalating furosemide doses. The disagreement is what to actually change: the dosing strategy of the same drug, or the drug class attacking the nephron.

A single patient with CKD stage 3b needing urgent coronary angiography for NSTEMI. The disagreement is whether any specific prophylactic regimen beyond straightforward isotonic saline actually changes her risk.

A single patient with necrotizing soft-tissue infection now on continuous renal replacement therapy. The disagreement is how to dose life-saving antibiotics through a clearance mechanism that no standard renal-dosing chart was built to describe.

A single patient with severe combined metabolic acidosis and acute kidney injury from suspected mesenteric ischemia. The disagreement is what treating the pH number can still be expected to buy, now that the trial built to test that subgroup has reported.

A single patient with severe hyperkalemia, ECG changes, and new oliguric AKI on a background of chronic ACE-inhibitor therapy. The disagreement is whether medical management has genuinely bought enough time, or whether the ECG has already answered that question.

A single patient, minutes into septic shock resuscitation. The disagreement is whether the specific crystalloid hanging on the pole meaningfully changes her odds of kidney injury, or whether that question has already been answered more ambiguously than either side wants to admit.

A single patient with decompensated cirrhosis and hepatorenal-pattern AKI needing CRRT. The disagreement is whether an anticoagulant metabolized by the liver is a genuine contraindication, or whether the alternative brings its own real risk in a patient who cannot afford to bleed.

A single patient recovering from AKI, on chronic ACE-inhibitor therapy for proteinuric kidney disease that was held on admission. The disagreement is not whether to resume it eventually, but whether today's creatinine trend is confirmation enough to do it now.

A single patient found down after an eighteen-hour fall with a markedly elevated creatine kinase. The disagreement is whether adding bicarbonate and mannitol to her fluid resuscitation actually protects her kidneys beyond what aggressive isotonic fluid alone already does.

A single patient about to start induction chemotherapy for a high-tumor-burden lymphoma. The disagreement is whether the faster, more expensive drug is worth starting chemotherapy today rather than waiting one more day for a screening result.